Open AccessOutcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
Author(s) -
Frank L. van de Veerdonk,
Ilse J.E. Kouijzer,
Aline de Nooijer,
Hans G. van der Hoeven,
Coen Maas,
Mihai G. Netea,
Roger J. M. Brüggemann
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.17708
Subject(s) - icatibant , covid-19 , kinin , antagonist , medicine , receptor antagonist , bradykinin , receipt , receptor , pharmacology , virology , disease , infectious disease (medical specialty) , computer science , outbreak , world wide web
This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom